Quarterly report pursuant to Section 13 or 15(d)

Revenue - Potential Milestone Payments (Details)

v3.19.1
Revenue - Potential Milestone Payments (Details) - Strategic Partnerships and Other License Agreements - USD ($)
$ in Millions
Dec. 31, 2018
Dec. 31, 2017
Research, Development & Commercial Milestones    
Revenue Recognition, Milestone Method [Line Items]    
Total potential milestone payments $ 2,851  
Research, Development & Commercial Milestones | AstraZeneca    
Revenue Recognition, Milestone Method [Line Items]    
Total potential milestone payments 769  
Research, Development & Commercial Milestones | Servier    
Revenue Recognition, Milestone Method [Line Items]    
Total potential milestone payments 1,111  
Research, Development & Commercial Milestones | Seattle Genetics    
Revenue Recognition, Milestone Method [Line Items]    
Total potential milestone payments $ 971  
Sales Milestones    
Revenue Recognition, Milestone Method [Line Items]    
Total potential milestone payments   $ 2,291
Sales Milestones | AstraZeneca    
Revenue Recognition, Milestone Method [Line Items]    
Total potential milestone payments   450
Sales Milestones | Servier    
Revenue Recognition, Milestone Method [Line Items]    
Total potential milestone payments   960
Sales Milestones | Seattle Genetics    
Revenue Recognition, Milestone Method [Line Items]    
Total potential milestone payments   $ 881